Cilastatin

Cilastatin (MK0791) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin is an antibacterial adjunct[1][2][3].

Product Specifications

CAS Number

[82009-34-5]

Product Name Alternative

MK0791

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Cilastatin.html

Concentration

10mM

Purity

99.91

Solubility

1M NaOH : 100 mg/mL (ultrasonic; adjust pH to 12 with NaOH) |DMSO : 100 mg/mL (ultrasonic) |H2O : 5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(O)/C(NC([C@@H]1C(C)(C)C1)=O)=C/CCCCSC[C@H](N)C(O)=O

Molecular Formula

C16H26N2O5S

Molecular Weight

358.45

Precautions

H302, H315, H319, H335

References & Citations

[1]The renal membrane dipeptidase (dehydropeptidase I) inhibitor, cilastatin, inhibits the bacterialmetallo-beta-lactamase enzyme CphA. Antimicrob Agents Chemother. 1995 Jul;39 (7) :1629-31.|[2]Blanca Humanes, et al. Protective Effects of Cilastatin Against Vancomycin-Induced Nephrotoxicity. Biomed Res Int. 2015;2015:704382.|[3]P J Petersen, et al. In Vitro and in Vivo Activities of LJC10,627, a New Carbapenem With Stability to Dehydropeptidase I. Antimicrob Agents Chemother. 1991 Jan;35 (1) :203-7.